• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Alvotech upgraded by Barclays with a new price target

    1/29/24 7:03:36 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALVO alert in real time by email
    Barclays upgraded Alvotech from Equal Weight to Overweight and set a new price target of $17.00 from $10.00 previously
    Get the next $ALVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALVO

    DatePrice TargetRatingAnalyst
    2/14/2025$18.00Buy
    UBS
    1/29/2024$10.00 → $17.00Equal Weight → Overweight
    Barclays
    10/20/2023$5.00 → $10.00Sell → Neutral
    Citigroup
    9/21/2023$10.00Equal Weight
    Barclays
    9/7/2022$10.00Equal-Weight
    Morgan Stanley
    9/6/2022$12.00 → $5.00Buy → Sell
    Citigroup
    More analyst ratings

    $ALVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Alvotech with a new price target

      UBS initiated coverage of Alvotech with a rating of Buy and set a new price target of $18.00

      2/14/25 9:00:38 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech upgraded by Barclays with a new price target

      Barclays upgraded Alvotech from Equal Weight to Overweight and set a new price target of $17.00 from $10.00 previously

      1/29/24 7:03:36 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech upgraded by Citigroup with a new price target

      Citigroup upgraded Alvotech from Sell to Neutral and set a new price target of $10.00 from $5.00 previously

      10/20/23 7:21:31 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVO
    SEC Filings

    See more
    • SEC Form 6-K filed by Alvotech

      6-K - Alvotech (0001898416) (Filer)

      6/23/25 6:00:13 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Alvotech

      6-K - Alvotech (0001898416) (Filer)

      6/12/25 5:17:47 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Alvotech

      6-K - Alvotech (0001898416) (Filer)

      6/11/25 6:00:49 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care